Patient reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD refractory rheumatoid arthritis

Assess- ment of QOL was based on the Spanish version of the Health Assessment Questionnaire Disability Index (Span- ish HAQ-DI) [26] administered the same day as the foot

(ETN): Etanercept; (MTX): Methotrexate; (DMARDs): Disease modifying antirheumatic drugs; (PRO): Patient reported outcome; (RA): Rheumatoid arthritis; (HAQ): Health

HRQoL: Health related quality of life; MCS: Mental Component Summary; MDHAQ: Multi-Dimensional Health Assessment Questionnaire; PCS: Physical Component Summary; PN: Pain;

To measure lim- itations in physical functioning, the multi-item Health Assessment Questionnaire (HAQ), expressed as a disability index (DI) from 0 (no disability) to 3

Measures of rheumatoid arthritis disease activ- ity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and

Assessments were conducted before and after intervention using the Pain Disability Index (PDI) to measure pain and functioning, the Health Assessment Questionnaire (HAQ) for

Four of the patient-reported outcome measures considered (the Ankle Osteoarthritis Scale, the Manchester Foot Pain and Disability Index, the Foot and Ankle Ability Measure and

Nevertheless, this study indicated that PROs reflecting physical aspects (pain, functional disability, PGA, physical quality of life) were more modulated by this biologic